Serum 25-Hydroxyvitamin D Concentrations ≥40 ng/ml Are Associated with >65% Lower Cancer Risk: Pooled Analysis of Randomized Trial and Prospective Cohort Study.
about
Evaluation of vitamin D3 intakes up to 15,000 international units/day and serum 25-hydroxyvitamin D concentrations up to 300 nmol/L on calcium metabolism in a community setting.Randomized controlled trials of vitamin D and cancer incidence: A modeling study.Standardizing 25-hydroxyvitamin D data from the HunMen cohort.Dietary Supplements Commonly Used by Cancer Survivors: Are There Any Benefits?Plasma 25-Hydroxyvitamin D3 Levels in Colorectal Cancer Patients and Associations with Physical Activity.Vitamin D: a 'wanted' supernatural power or a power of wishful thinking.High Prevalence of Vitamin D Deficiency in Patients with Bone Tumors.Vitamin D and mental health: optimizing in the midst of the complexity.Vitamin D and Breast Cancer: Latest Evidence and Future Steps.Association between Vitamin D Genetic Risk Score and Cancer Risk in a Large Cohort of U.S. Women.Vitamin D research and public health nutrition: a current perspective.25-hydroxyvitamin D, influenza vaccine response and healthcare encounters among a young adult population.Both high and low plasma levels of 25-hydroxy vitamin D increase blood pressure in a normal rat model.Sunbeds with UVB radiation can produce physiological levels of serum 25-Hydroxyvitamin D in healthy volunteers.Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort.Correction: Serum 25-Hydroxyvitamin D Concentrations ≥40 ng/ml Are Associated with >65% Lower Cancer Risk: Pooled Analysis of Randomized Trial and Prospective Cohort Study
P2860
Q33595839-3B0852B7-D5D8-4F52-9E3E-78F24F77C49EQ33620889-947C0FFD-5738-42F0-ADEB-0510B193262FQ36315735-57CA2829-93CA-452C-B6B8-9B0CD787FEEDQ38622264-1861D163-DC0A-4490-B210-74CD729BBE48Q40377781-71ADAFFF-5931-4622-ADC3-D5A077D3E28DQ41940720-77D03F50-BA6A-413B-936E-645B11C05650Q47299545-0DB24840-58A7-44B0-85E8-E7282B480A34Q47709871-ABE602DC-24A9-4727-ACC9-71B76B0ACACEQ49419009-C4E9D1B4-FF94-43E5-916C-1FEFDC0F1CAFQ49422606-00958E22-F4F2-42D8-8A98-B031D94C81EAQ50072023-02B3D0D3-B473-401B-9970-F55005CBE974Q50099209-D13563A6-C625-4B9E-B7C1-9AC26C138A50Q51013806-5B5352DE-1E29-4FA1-AFF5-8CDE4889AED3Q55005087-6930ABA5-F7EA-4C19-BAC4-20AB9F3A3B96Q55360424-214340DD-4923-4A74-9392-8F2010230AC0Q56890151-9819C644-EEBE-4E4A-8CDB-77A91C301FF8
P2860
Serum 25-Hydroxyvitamin D Concentrations ≥40 ng/ml Are Associated with >65% Lower Cancer Risk: Pooled Analysis of Randomized Trial and Prospective Cohort Study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Serum 25-Hydroxyvitamin D Conc ...... and Prospective Cohort Study.
@ast
Serum 25-Hydroxyvitamin D Conc ...... and Prospective Cohort Study.
@en
type
label
Serum 25-Hydroxyvitamin D Conc ...... and Prospective Cohort Study.
@ast
Serum 25-Hydroxyvitamin D Conc ...... and Prospective Cohort Study.
@en
prefLabel
Serum 25-Hydroxyvitamin D Conc ...... and Prospective Cohort Study.
@ast
Serum 25-Hydroxyvitamin D Conc ...... and Prospective Cohort Study.
@en
P2093
P2860
P1433
P1476
Serum 25-Hydroxyvitamin D Conc ...... and Prospective Cohort Study.
@en
P2093
Carole Baggerly
Cedric F Garland
Christine B French
Edward D Gorham
Joan M Lappe
Leo L Baggerly
Robert P Heaney
Sharon L McDonnell
P2860
P304
P356
10.1371/JOURNAL.PONE.0152441
P407
P577
2016-04-06T00:00:00Z